Literature DB >> 33630820

Detection of B.1.351 SARS-CoV-2 Variant Strain - Zambia, December 2020.

Mulenga Mwenda, Ngonda Saasa, Nyambe Sinyange, George Busby, Peter J Chipimo, Jason Hendry, Otridah Kapona, Samuel Yingst, Jonas Z Hines, Peter Minchella, Edgar Simulundu, Katendi Changula, King Shimumbo Nalubamba, Hirofumi Sawa, Masahiro Kajihara, Junya Yamagishi, Muzala Kapin'a, Nathan Kapata, Sombo Fwoloshi, Paul Zulu, Lloyd B Mulenga, Simon Agolory, Victor Mukonka, Daniel J Bridges.   

Abstract

The first laboratory-confirmed cases of coronavirus disease 2019 (COVID-19), the illness caused by SARS-CoV-2, in Zambia were detected in March 2020 (1). Beginning in July, the number of confirmed cases began to increase rapidly, first peaking during July-August, and then declining in September and October (Figure). After 3 months of relatively low case counts, COVID-19 cases began rapidly rising throughout the country in mid-December. On December 18, 2020, South Africa published the genome of a SARS-CoV-2 variant strain with several mutations that affect the spike protein (2). The variant included a mutation (N501Y) associated with increased transmissibility.†,§ SARS-CoV-2 lineages with this mutation have rapidly expanded geographically.¶,** The variant strain (PANGO [Phylogenetic Assignment of Named Global Outbreak] lineage B.1.351††) was first detected in the Eastern Cape Province of South Africa from specimens collected in early August, spread within South Africa, and appears to have displaced the majority of other SARS-CoV-2 lineages circulating in that country (2). As of January 10, 2021, eight countries had reported cases with the B.1.351 variant. In Zambia, the average number of daily confirmed COVID-19 cases increased 16-fold, from 44 cases during December 1-10 to 700 during January 1-10, after detection of the B.1.351 variant in specimens collected during December 16-23. Zambia is a southern African country that shares substantial commerce and tourism linkages with South Africa, which might have contributed to the transmission of the B.1.351 variant between the two countries.

Entities:  

Mesh:

Year:  2021        PMID: 33630820     DOI: 10.15585/mmwr.mm7008e2

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  44 in total

1.  An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques.

Authors:  Yongjun Sui; Jianping Li; Hanne Andersen; Roushu Zhang; Sunaina K Prabhu; Tanya Hoang; David Venzon; Anthony Cook; Renita Brown; Elyse Teow; Jason Velasco; Laurent Pessaint; Ian N Moore; Laurel Lagenaur; Jim Talton; Matthew W Breed; Josh Kramer; Kevin W Bock; Mahnaz Minai; Bianca M Nagata; Hyoyoung Choo-Wosoba; Mark G Lewis; Lai-Xi Wang; Jay A Berzofsky
Journal:  PNAS Nexus       Date:  2022-06-17

2.  Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern.

Authors:  Christian Setz; Maximilian Große; Janina Auth; Maria Fröba; Pia Rauch; Alexander Bausch; Matthew Wright; Ulrich Schubert
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

3.  Efficacy and Safety of Blood Derivative Therapy for Patients with COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Zhangcheng Fei; Zhongsheng Chen; Xi Du; Haijun Cao; Changqing Li
Journal:  Transfus Med Hemother       Date:  2022-04-25       Impact factor: 4.040

4.  Identifying COVID-19 Severity-Related SARS-CoV-2 Mutation Using a Machine Learning Method.

Authors:  Feiming Huang; Lei Chen; Wei Guo; Xianchao Zhou; Kaiyan Feng; Tao Huang; Yudong Cai
Journal:  Life (Basel)       Date:  2022-05-28

5.  SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities.

Authors:  Rochelle P Walensky; Henry T Walke; Anthony S Fauci
Journal:  JAMA       Date:  2021-03-16       Impact factor: 157.335

6.  SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.

Authors:  Markus Hoffmann; Prerna Arora; Rüdiger Groß; Alina Seidel; Bojan F Hörnich; Alexander S Hahn; Nadine Krüger; Luise Graichen; Heike Hofmann-Winkler; Amy Kempf; Martin S Winkler; Sebastian Schulz; Hans-Martin Jäck; Bernd Jahrsdörfer; Hubert Schrezenmeier; Martin Müller; Alexander Kleger; Jan Münch; Stefan Pöhlmann
Journal:  Cell       Date:  2021-03-20       Impact factor: 41.582

7.  Immune transcriptomes from hospitalized patients infected with the SARS-CoV-2 variants B.1.1.7 and B.1.1.7 carrying the E484K escape mutation.

Authors:  Hye Kyung Lee; Ludwig Knabl; Ludwig Knabl; Manuel Wieser; Anna Mur; August Zabernigg; Jana Schumacher; Norbert Kaiser; Priscilla A Furth; Lothar Hennighausen
Journal:  medRxiv       Date:  2021-05-30

8.  Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America.

Authors:  Elena Quinonez; Majid Vahed; Abdolrazagh Hashemi Shahraki; Mehdi Mirsaeidi
Journal:  Viruses       Date:  2021-05-17       Impact factor: 5.048

Review 9.  The Emerging Concern and Interest SARS-CoV-2 Variants.

Authors:  Edyta Janik; Marcin Niemcewicz; Marcin Podogrocki; Ireneusz Majsterek; Michal Bijak
Journal:  Pathogens       Date:  2021-05-21

Review 10.  Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19).

Authors:  Ting Wu; Shuntong Kang; Wenyao Peng; Chenzhe Zuo; Yuhao Zhu; Liangyu Pan; Keyun Fu; Yaxian You; Xinyuan Yang; Xuan Luo; Liping Jiang; Meichun Deng
Journal:  Front Med (Lausanne)       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.